Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | PPARD | Q03181 | 7/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130971 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9187078 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9520074 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9955037 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL2199706 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL2202520 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9953336 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL2269030 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL9955629 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA | |
| SCHEMBL538816 | 1.00 | CES2 (0.44) | CES2GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1782791-B2 | Cosmetic composition comprising a cationic surfactant,a liquid fatty material and a sorbitan ester | OREAL (FR) | 2019-01-23 | — | — | EP | claimed |
| EP-1782791-B1 | Cosmetic composition comprising a cationic surfactant,a liquid fatty material and a sorbitan ester | OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-20070122508-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | HELIXIR CO., LTD. (KR) | 2007-05-31 | — | — | US | claimed |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | MEDIHELPLINE CO., LTD (KR) | 2026-05-05 | — | — | US | disclosed |
| WO-2023149785-A1 | COMPOSITION FOR PREVENTION AND TREATMENT OF INFLAMMATORY EDEMA, COMPRISING LYSIMACHIA CHRISTINAE HANCE EXTRACT AS ACTIVE INGREDIENT | 경희대학교 산학협력단 | 2023-08-10 | — | — | WO | disclosed |
| WO-2023149791-A1 | COMPOSITION COMPRISING EXTRACT OF PHASEOLUS ANGULARIS WIGHT AS ACTIVE INGREDIENT FOR PREVENTING AND TREATING INFLAMMATORY EDEMA | 경희대학교 산학협력단 | 2023-08-10 | — | — | WO | disclosed |
| WO-2023101440-A1 | ANTI-INFLAMMATORY COMPOSITION, CONTAINING EXTRACT OF GOLD NANOPARTICLE-PEANUT SPROUT AS ACTIVE INGREDIENT | 경희대학교 산학협력단 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023096345-A1 | COMPOSITION FOR PREVENTING OR TREATING MUSCLE DISEASE COMPRISING SARGASSUM SERRATIFOLIUM EXTRACT | 부경대학교 산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| US-20230127213-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF | PARK, OK NAM (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230103514-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF | MEDIHELPLINE CO., LTD (KR) | 2023-04-06 | — | — | US | disclosed |
| US-20230100173-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF | MEDIHELPLINE CO., LTD (KR) | 2023-03-30 | — | — | US | disclosed |
| WO-2007004832-A1 | COMPOSITION COMPRISING AN EXTRACT OF CRINUM ASIATICUM LINNE HAVING ANTI-ALLERGIC AND ANTI-INFLAMMATORY ACTIVITY | BIOLAND LTD. (KR) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006093793-A2 | COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF | EFFICAS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006090939-A1 | COSMETIC COMPOSITION COMPRISING BETA-FRUCTOSYL-L-ASCORBIC ACID FOR SKIN WHITENING | BIOLAND LTD. (KR) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006016728-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS | HELIXIR CO., LTD. (KR) | 2006-02-16 | — | — | WO | disclosed |
| EP-1551433-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE | Pangenomics Co., Ltd. (KR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004096171-A1 | SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004017982-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE | PANGENOMICS CO., LTD (KR) | 2004-03-04 | — | — | WO | disclosed |
| US-20040037909-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | VIROMED CO., LTD. (KR) | 2004-02-26 | — | — | US | disclosed |
| EP-0785952-B1 | GRAFT CERAMIDE HAVING AN ANTI-ELASTASE PROPERTY | FABRE PIERRE DERMO COSMETIQUE (FR) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | CUTA, VEGFA, MMP8 | CES2 4399/4885GPR84 3533/4885PPARG 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.